Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Efficacy of LX102-C01 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Authors not listed

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · 2021

Abstract

The goal of this study is to evaluate the safety and efficacy of LX102-C01 treatment of nAMD. This study will enroll subjects aged ≥ 50 years old to receive a single unilateral intravitreal (IVT) injection of LX102-C01 to evaluate its safety and efficacy.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-09 MST

Cite this

APA
Anonymous. (2021). An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Efficacy of LX102-C01 in Patients With Neovascular Age-Related Macular Degeneration (nAMD). <em>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</em>. https://clinicaltrials.gov/study/NCT05831007
Vancouver
Anonymous. An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Efficacy of LX102-C01 in Patients With Neovascular Age-Related Macular Degeneration (nAMD). Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. 2021.
BibTeX
@misc{anon2021AnOpen, title = {An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Efficacy of LX102-C01 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)}, author = {Anonymous}, journal = {Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine}, year = {2021}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings